Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Federal Trade Commission
Covington
Chubb
US Army

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,028,071

« Back to Dashboard

Which drugs does patent 6,028,071 protect, and when does it expire?

Patent 6,028,071 protects FOLOTYN and is included in one NDA.

This patent has thirteen patent family members in nine countries.

Summary for Patent: 6,028,071
Title: Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Abstract:Highly purified 10-propargyl-10-deazaaminopterin (10-propargyl-10dAM) compositions tested in xenograft models for their efficacy against human tumors are shown to be far superior to methotrexate ("MTX") and are even superior to the newer clinical candidate edatrexate ("EDX"). Moreover, 10-propragyl-10dAM showed a surprising ability to cure tumors such that there was no evidence of tumor growth several weeks after the cessation of therapy. Thus, highly purified compositions containing 10-propargyl-10dAM can be used to treat human tumors, particularly human mammary tumors and human lung cancer.
Inventor(s): Sirotnak; Francis M. (New York, NY), Piper; James R. (Birmingham, AL), DeGraw; Joseph I. (Missoula, MT), Colwell; William T. (Menlo Park, CA)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY) SRI International (Menlo Park, CA) Southern Research Institute (Birmingham, AL)
Application Number:09/214,984
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,028,071
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,028,071
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,028,071

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allos FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-001 Sep 24, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA ➤ Sign Up
Allos FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-002 Sep 24, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,028,071

PCT Information
PCT FiledJuly 16, 1997PCT Application Number:PCT/US97/11982
PCT Publication Date:January 22, 1998PCT Publication Number: WO98/02163

International Family Members for US Patent 6,028,071

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 407677 ➤ Sign Up
Canada 2260266 ➤ Sign Up
Germany 69738981 ➤ Sign Up
Denmark 0944389 ➤ Sign Up
European Patent Office 0944389 ➤ Sign Up
European Patent Office 1891957 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
UBS
Harvard Business School
Julphar
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.